UK Govt. extends contract with Wockhardt for manufacture of COVID-19 vaccines

Wockhardt announced that it has been awarded a six-month extension of its agreement with the UK Government to fill-finish COVID-19 vaccines. This expands the original agreement from 18 to 24 months i.e., until August 2022 and the manufacturing will continue to be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales.

Powered by Capital Market - Live News